Provention Bio Announces U.S. FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individ

Sam Martin, Argot Partners
sam@argotpartners.com? ?
212-600-1902 Media Contact:
Lori Rosen, LDR Communications
lori@ldrcommunications.com?
917-553-6808 SOURCE Provention Bio, Inc.